×
News Home

Does Adaptimmune Therapeutics PLC - ADR (ADAP) Have What it Takes to be in Your Portfolio Thursday?

Thursday, August 11, 2022 03:40 PM | InvestorsObserver Analysts
Does Adaptimmune Therapeutics PLC - ADR (ADAP) Have What it Takes to be in Your Portfolio Thursday?

The 75 rating InvestorsObserver gives to Adaptimmune Therapeutics PLC - ADR (ADAP) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 88 percent of stocks in the Biotechnology industry, ADAP’s 75 overall rating means the stock scores better than 75 percent of all stocks.

Overall Score - 75
ADAP has an Overall Score of 75. Find out what this means to you and get the rest of the rankings on ADAP!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.
This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Adaptimmune Therapeutics PLC - ADR Stock Today?

Adaptimmune Therapeutics PLC - ADR (ADAP) stock is trading at $2.22 as of 3:24 PM on Thursday, Aug 11, a drop of -$0.08, or -3.44% from the previous closing price of $2.30. The stock has traded between $2.22 and $2.36 so far today. Volume today is light. So far 144,753 shares have traded compared to average volume of 257,642 shares. Click Here to get the full Stock Report for Adaptimmune Therapeutics PLC - ADR stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App